Was everyone wrong about fish oil? Is venture capital a cartel? And what’s with all those ketamine clinics?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a recap of the news that shocked biotech: A prescription-grade fish oil significantly reduced the risks of heart attacks and strokes. Then we talk to STAT’s Megan Thielking about her investigation into the rapid rise — and considerable risks — of clinics offering ketamine as an off-label treatment for depression. And biotech entrepreneur Ethan Perlstein joins us to talk about the flaws he sees in biotech’s venture capital model. Finally, there’s a lightning round, exploring identical migraine drugs, impoverished pharma CEOs, and why hedge fund managers can’t get enough of drug stocks.

For more on what we cover, here’s the fish oil news; and here’s the story on off-label ketamine.

advertisement

We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email readoutloud@statnews.com.

advertisement


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at marketing@statnews.com.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy